BridgeMD
Pharmacokinetics of fluconazole given orally or intravenously as prophylaxis or therapy to children and adolescents with invasive fungal infections (FOCUS)
EU CTIS ID: 2024-518305-17-01
What this study is testing
To establish an improved fluconazole dosing regimen for paediatric and adolescent patients aged 2-18 years.
- Therapeutic use (Phase IV)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Subject is treated with fluconazole for prophylaxis or treatment of an invasive fungal infection;
- Subject is 2 - 18 years of age on the day of the first fluconazole dosing
- Subject is managed with a central venous catheter or arterial line from which blood can be obtained
You likely can't join if
- Subject is managed by means of an extracorporeal clearance technique
- Subject has previously participated in this study
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 0-17 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.